CA2494115A1 - Mutants de proteines ige et utilisations desdits mutants - Google Patents

Mutants de proteines ige et utilisations desdits mutants Download PDF

Info

Publication number
CA2494115A1
CA2494115A1 CA002494115A CA2494115A CA2494115A1 CA 2494115 A1 CA2494115 A1 CA 2494115A1 CA 002494115 A CA002494115 A CA 002494115A CA 2494115 A CA2494115 A CA 2494115A CA 2494115 A1 CA2494115 A1 CA 2494115A1
Authority
CA
Canada
Prior art keywords
seq
protein
ige
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002494115A
Other languages
English (en)
Inventor
Theodore S. Jardetzky
Beth A. Wurzburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/211,948 external-priority patent/US6889145B1/en
Application filed by Northwestern University filed Critical Northwestern University
Publication of CA2494115A1 publication Critical patent/CA2494115A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002494115A 2002-08-01 2003-08-01 Mutants de proteines ige et utilisations desdits mutants Abandoned CA2494115A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/211,948 US6889145B1 (en) 2000-03-15 2002-08-01 Three-dimensional model of a Fc region of an IgE antibody and uses thereof
US10/211,948 2002-08-01
US31944602P 2002-08-02 2002-08-02
US60/319,446 2002-08-02
PCT/US2003/024336 WO2004013158A2 (fr) 2002-08-01 2003-08-01 Mutants de proteines ige et utilisations desdits mutants

Publications (1)

Publication Number Publication Date
CA2494115A1 true CA2494115A1 (fr) 2004-02-12

Family

ID=31498036

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002494115A Abandoned CA2494115A1 (fr) 2002-08-01 2003-08-01 Mutants de proteines ige et utilisations desdits mutants

Country Status (5)

Country Link
EP (1) EP1527099A2 (fr)
JP (1) JP2006500923A (fr)
AU (1) AU2003278702A1 (fr)
CA (1) CA2494115A1 (fr)
WO (1) WO2004013158A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094420A1 (fr) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
US8058231B2 (en) * 2005-09-20 2011-11-15 Nihon University Transcriptional regulation of high affinity IgE receptor γ-chain
SI2494356T1 (sl) * 2009-10-26 2017-07-31 Genentech, Inc. Preizkusi za detektiranje protiteles, specifičnih za terapevtska protitelesa proti IgE, in njihova uporaba pri anafilaksi
GB2503883A (en) * 2012-07-09 2014-01-15 King S College London Variant IgE with reduced affinity to CD23

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells

Also Published As

Publication number Publication date
WO2004013158A2 (fr) 2004-02-12
JP2006500923A (ja) 2006-01-12
WO2004013158A3 (fr) 2004-08-26
EP1527099A2 (fr) 2005-05-04
AU2003278702A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
JP6228971B2 (ja) Ｃｔｌａ−４バリアント
Wurzburg et al. Structure of the human IgE-Fc Cε3-Cε4 reveals conformational flexibility in the antibody effector domains
US5965709A (en) IgE antagonists
JP2021090441A (ja) 調整可能な親和性を有する免疫調節タンパク質
CN110214148A (zh) 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
KR102132997B1 (ko) Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
JPH10503371A (ja) 新規化合物
EP2619229A2 (fr) Molécules de fusion multimères solubles à base d'il-15, leurs procédés de préparation et d'utilisation
CA2545539A1 (fr) Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
JP2022159401A (ja) 血中半減期の向上のための抗体Ｆｃ変異体
JP2023550191A (ja) Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法
CA2494115A1 (fr) Mutants de proteines ige et utilisations desdits mutants
US20040133356A1 (en) Three-dimensional model of a Fc region of an IgE antibody and uses thereof
TW202106703A (zh) Cd80變體蛋白及其用途
US20060036420A1 (en) Three-dimensional model of a complex between a Fc epsilon receptor alpha chain and a Fc region of an IgE antibody and uses thereof
EP2078091A2 (fr) Cristaux et structure du variant d'igg fc humain
JP7440516B2 (ja) 切断多価多量体
CN117222667A (zh) 用于治疗免疫失调的双功能分子
US20060063201A1 (en) Crystals of the Fc region of immunoglobulin epsilon heavy chain protein
US20040033527A1 (en) Methods of using a three-dimensional model of a Fc epsilon receptor alpha chain
CN113795502B (zh) Cd80变体蛋白及其应用
KR20230042638A (ko) FcγRⅢa 선택적 결합력 향상 당화 Fc 변이체들

Legal Events

Date Code Title Description
FZDE Dead